ABSTRACT
The PKR protein kinase is a critical component of the cellular antiviral and antiproliferative responses induced by interferons. Recent evidence indicates that the nonstructural 5A (NS5A) protein of hepatitis C virus (HCV) can repress PKR function in vivo, possibly allowing HCV to escape the antiviral effects of interferon. NS5A presents a unique tool by which to study the molecular mechanisms of PKR regulation in that mutations within a region of NS5A, termed the interferon sensitivity-determining region (ISDR), are associated with sensitivity of HCV to the antiviral effects of interferon. In this study, we investigated the mechanisms of NS5A-mediated PKR regulation and the effect of ISDR mutations on this regulatory process. We observed that the NS5A ISDR, though necessary, was not sufficient for PKR interactions; we found that an additional 26 amino acids (aa) carboxyl to the ISDR were required for NS5A-PKR complex formation. Conversely, we localized NS5A binding to within PKR aa 244 to 296, recently recognized as a PKR dimerization domain. Consistent with this observation, we found that NS5A from interferon-resistant HCV genotype 1b disrupted kinase dimerization in vivo. NS5A-mediated disruption of PKR dimerization resulted in repression of PKR function and inhibition of PKR-mediated eIF-2α phosphorylation. Introduction of multiple ISDR mutations abrogated the ability of NS5A to bind to PKR in mammalian cells and to inhibit PKR in a yeast functional assay. These results indicate that mutations within the PKR-binding region of NS5A, including those within the ISDR, can disrupt the NS5A-PKR interaction, possibly rendering HCV sensitive to the antiviral effects of interferon. We propose a model of PKR regulation by NS5A which may have implications for therapeutic strategies against HCV.
ACKNOWLEDGMENTS
We thank Pat McGifford and the University of Washington photography service for excellent data photos. We are grateful to Dagma Daniel for excellent administrative support. We thank T. Dever (National Institute of Child Health and Human Development) and T. Imagawa (Osaka University) for antibodies to yeast eIF-2α and NS5A, respectively.
This work was supported in part by National Institutes of Health grants AI22646, RR00166, and AI41629 (M.G.K.) and AI41320-02 and AI39049-02 (D.R.G.) and by grants from the University of Washington Royalty Research Fund, Schering Plough, and Ribogene Corporation, Hayward, Calif. M.D. is a Howard Hughes undergraduate research fellow. M.G. is supported by the Helen Hay Whitney Foundation.